Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Leases: 2020-2025

Historic Operating Leases for Enanta Pharmaceuticals (ENTA) over the last 6 years, with Sep 2025 value amounting to $54.8 million.

  • Enanta Pharmaceuticals' Operating Leases rose 1.51% to $54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 1.51%. This contributed to the annual value of $54.8 million for FY2025, which is 1.51% up from last year.
  • Enanta Pharmaceuticals' Operating Leases amounted to $54.8 million in FY2025, which was up 1.51% from $53.9 million recorded in FY2024.
  • Enanta Pharmaceuticals' 5-year Operating Leases high stood at $54.8 million for FY2025, and its period low was $1.1 million during FY2021.
  • Its 3-year average for Operating Leases is $43.3 million, with a median of $53.9 million in 2024.
  • In the last 5 years, Enanta Pharmaceuticals' Operating Leases slumped by 70.66% in 2021 and then skyrocketed by 1,886.86% in 2022.
  • Over the past 5 years, Enanta Pharmaceuticals' Operating Leases (Yearly) stood at $1.1 million in 2021, then spiked by 1,886.86% to $22.4 million in 2022, then fell by 5.07% to $21.2 million in 2023, then skyrocketed by 153.99% to $53.9 million in 2024, then grew by 1.51% to $54.8 million in 2025.